Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Organon and Co
- Study ID
- NCT03956355
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tapinarof — DRUGTapinarof cream, 1%, applied once daily
- Vehicle Cream — DRUGVehicle cream applied once daily
Study Details
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
Key Dates
- Start date
- May 21, 2019
- Status verified
- Sep 2022
- Primary completion
- May 26, 2020
- Completion
- May 26, 2020
Study Design
- Enrollment
- 510 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Tapinarof (DMVT-505)Tapinarof (DMVT-505) Cream Group
- Placebo Comparator: Vehicle CreamVehicle Cream Group
Primary Outcome Measure
Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation [ Time Frame: Baseline to Week 12 ]
Locations (44)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Understanding Participation Habits Among Plaque Psoriasis PatientsNot Yet Recruiting · Power Life Sciences Inc. · San Francisco, California
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisPHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque PsoriasisPHASE1 · Recruiting · Ascletis Pharma (China) Co., Limited · Miami, Florida
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama